Bevacizumab may be active in myelofibrosis.
A case of a 69-year-old woman with myelofibrosis presenting with non-small cell lung cancer was reported at Sotiria General Hospital in Athens. She was administered bevacizumab infusions biweekly and a great decrease in the number of her white blood cells was observed. Such low levels of white blood cells had never been reached in the past, when she was receiving hydroxyurea.
Nikolaidis
Ilias
I
Makrilia
Nektaria
N
Xyla
Vassilia
V
Dilana
Kalliopi
K
Stathopoulos
Dimitris
D
Meletis
Ioannis
I
Syrigos
Kostas
K
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000098:blood supply / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007263:Infusions, Parenteral; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000097:blood / Q000098:blood supply / Q000188:drug therapy*; D055728:Primary Myelofibrosis / Q000097:blood / Q000188:drug therapy*; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006918:Hydroxyurea